B-cell targeting: A novel approach to immune intervention today and tomorrow

Expert Opinion on Biological Therapy

Volumn 7, Issue 9, 2007, Pages 1287-1299

  Dörner, Thomas ^a   Lipsky, Peter E ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Autoimmunity; B cells; Biologics; Rheumatoid arthritis; Systemic lupus erythematosus; Targeted therapy

Indexed keywords

ABATACEPT; ABETIMUS; ALEMTUZUMAB; AMG 623; ATLIZUMAB; B LYMPHOCYTE ANTIBODY; BELIMUMAB; CD20 ANTIBODY; CORTISONE; CYCLOPHOSPHAMIDE; ECULIZUMAB; EDRATIDE; ENZYME INHIBITOR; EPRATUZUMAB; FC RECEPTOR; HUMANIZED ANTIBODY 20; HYBRID PROTEIN; IMATINIB; INTERFERON ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD19; MONOCLONAL ANTIBODY CD22; OCRELIZUMAB; OFATUMUMAB; PROTEIN TRU 015; RG 2077; RITUXIMAB; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL ACTIVITY; CELL DEATH; CELL MATURATION; CELL SURVIVAL; CELL THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; DRY EYE; FATIGUE; GERMINAL CENTER; HUMAN; INFECTION; INJECTION SITE REACTION; INTERVENTION STUDY; LEUKOENCEPHALOPATHY; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL DEPLETION; TARGET CELL; THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION;

EID: 34748865647     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.9.1287     Document Type: Review

References (119)

1. DE VITA S, ZAJA F, SACCO S, DE CANDIA A, FANIN R, FERRACCIOLI G: Efficacy of selective B ceil blockade in the treatment of rheumatoid arthritis - evidence for a pathogenetic role of B cells. Arthritis Rheum. (2002) 46:2029-2033.
2. D RNER T, BURMESTER GR: The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr. Opin. Rheumatol. (2003) 15:246-252.
3. EDWARDS JCW, CAMBRIDGE G: Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (2001) 40:205-211.
4. LEANDRO MJ, EDWARDS JCW, EHRENSTEIN MR, CAMBRIDGE G, ISENBERG DA: B lymphocyte depletion in the treatment of systemic lupus erythematosus. Arthritis Rheum. (2004) 50:S447.
5. LIPSKY PE: Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. (2001) 2:764-766.
6. MARTIN F, CHAN AC: Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity (2004) 20:517-527.
7. BAECKLUND E, EKBOM A, SPAREN P, FELTELIUS N, KLARESKOG L: Disease activity determines lymphoma risk in patients with rheumatoid arthritis. A nested case-control study. Arthritis Rheum. (1997) 40:1696.
8. VOULGARELIS M, DAFNI UG, ISENBERG KA, MOUTSOPOULOS HM: Malignant lymphoma in primary Sjogren's syndrome - a multicenter, retrospective, clinical study by the European concerted action on Sjogren's syndrome. Arthritis Rheum. (1999) 42:1765-1772.
9. DIAMOND B: Systemic lupus erythematosus and Sjogren syndrome. Curr. Opin. Rheumatol. (2006) 18:449-450.
10. DÖRNER T: Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J. Rheumatol. (2006) 33:3-11.
11. DÖRNER T, LIPSKY PE: Signalling pathways in B cells: implications for autoimmunity. Curr. Top. Microbiol. Immunol. (2006) 305:213-240.
12. MILNER ECB, ANOLIK J, CAPPIONEA, SANZ I: Human innate B cells: a link between host defense and autoimmunity? Springer Semin. Immunopathol. (2005) 26:433-452.
13. HANSEN A, GOSEMANN M, PRUSS A et al.: Abnormalities in peripheral B cell memory of patients with primary Sjogren's syndrome. Arthritis Rheum. (2004) 50:1897-1908.
14. TARLINTON D: B-cell memory: are subsets necessary? Nat. Rev. Immunol. (2006) 6:785-790.
15. BENDELAC A, BONNEVILLE M, KEARNEY JF: Autoreactivity by design: innate B and T lymphocytes. Nat. Rev. Immunol. (2001) 1:177-186.
16. RADBRUCH A, MUEHLINGHAUS G, LUGER EO et al.: Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. (2006) 6:741-750.
17. MCHEYZER-WILLIAMS LJ, MCHEYZER-WlLLIAMS MG: Antigen-specific memory B cell development. Annu. Rev. Immunol. (2005) 23:487-513.
18. ODENDAHL M, MEI H, HOYER BF et al.: Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood (2005) 105:1614-1621.
19. MANSER T: Textbook germinal centers? J. Immunol. (2004) 172:3369-3375.
20. NIELEN MM, VAN SCHAARDENBURG D, VAN DE STADT RJ et al.: Autoantibodies and C-reactive protein levels in serum of blood donors before the onset of rheumatoid arthritis. Transfusion (2004) 44:A81.
21. KUNKEL HG, TAN EM: Autoantibodies and disease. Adv. Immunol. (1964) 4:351-395.
22. WARDEMANN H, YURASOV S, SCHAEFER A, YOUNG JW, MEFFRE E, NUSSENZWEIG MC: Predominant autoantibody production by early human B cell precursors. Science (2003) 301:1374-1377.
23. GOODNOW CC, SPRENT J, FAZEKAS DE ST GROTH B, VINUESA CG: Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature (2005) 435:590-597.
24. YURASOV S, WARDEMANN H, HAMMERSEN J et al.: Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. (2005) 201:703-711.
25. SAMUELS J, NG YS, COUPILLAUD C, PAGET D, MEFFRE E: Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. (2005) 201:1659-1667.
26. DORNER T, LIPSKY PE: Molecular basis of immunoglobulin variable region gene usage in systemic autoimmunity. Clin. Exp. Med. (2005) 4:159-169.
27. TILLER T, TSUIJI M, YURASOV S, VELINZON K, NUSSENZWEIG MC, WARDEMANN H: Autoreactivity in human IgG(+) memory B cells. Immunity (2007) 26:205-213.
28. CHAN OTM, HANNUM LG, HABERMAN AM, MADAIO MP, SHLOMCHIK MJ: A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. (1999) 189:1639-1647.
29. CHAN OTM, MADAIO MP, SHLOMCHIK MJ: The central and multiple roles of B cells in lupus pathogenesis. Immunol. Rev. (1999) 169:107-121.
30. + memory population. Arthritis Rheum. (2002) 46:S597.
31. HANSEN A, JACOBI A, PRUSS A et al.: Comparison of immunoglobulin heavy chain rearrangements between peripheral and glandular B cells in a patient with primary Sjogren's syndrome. Scan. J. Immunol. (2003) 57:470-479.
32. HANSEN A, REITER K, ZIPRIAN T et al.: Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjogren's syndrome. Arthritis Rheum. (2005) 52:2109-2119.
33. HANSEN A, DÖRNER T, LIPSKY PE: Chemokine receptor expression by peripheral blood B lymphocytes in patients with primary Sjogren's syndrome: comment on the article by Hansen et al.: Arthritis Rheum. (2006) 54:1708.
34. HENNEKEN M, DÖRNER T, BURMESTER GR, BEREK C: Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis. Res. Ther. (2005) 7:R1001-R1013.
35. HANSEN A, HOFFMANN A, DÖRNER T: Sjogren's syndrome - can we stratify the lymphoma risk? Aktuelle. Rheumatologie. (2005) 30:46-49.
36. HANSEN A, REITER K, PRUSS A et al.: Dissemination of a Sjogren's syndrome-associated extranoda marginal-zone B cell lymphoma - circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements. Arthritis Rheum. (2006) 54:127-137.
37. WEYAND CM, SEYLER T, GORONZY JJ: B cells in rheumatoid synovitis. Arthritis. Res. Ther. (2005) 7:S9-S12.
38. ZHANG X, HUPPERTS R, DE BAETS M: Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis. Immunol. Res. (2003) 28:61-78.
39. COLES AJ, COX A, LE PAGE E et al.: The window of therapeutic opportunity in multiple sclerosis. J. Neurol. (2006) 253:98-108.
40. EDWARDS JC, CAMBRIDGE G, LEANDRO MJ: Sustained improvement in rheumatoid arthritis following B lymphocyte depletion. Arthritis Rheum. (2000) 43:S391.
41. EDWARDS JCW, CAMBRIDGE G: B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. (2006) 6:394-403.
42. LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, EHRENSTElN MR, ISENBERG DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. (2002) 46:2673-2677.
43. POPA C, LEANDRO MJ, CAMBRIDGE G, EDWARDS JCW: Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology (2007) 46:626-630.
44. PIJPE J, BOOTSMA H, VAN IMHOFF G et al.: Rituximab (anti-CD20) for the treatment of primary Sjogren's syndrome. Arthritis Rheum. (2004) 50:S575.
45. LEANDRO MJ, EHRENSTEIN MR, EDWARDS JCW, MANSON J, CAMBRIDGE G, ISENBERG DA: Treatment of refractory lupus nephritis with B lymphocyte depletion. Arthritis Rheum. (2003) 48:S378.
46. BAR-OR A, CALABRESI P, ARNOLD D et al.: A Phase I, open-label, multicenteir study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS). Neurology (2007) 68:A84.
47. STASI R, PAGANO A, STIPA E, AMADORI S: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood (2001) 98:952-957.
48. LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus - a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum. (2004) 50:2580-2589.
49. VOS K, THURLINGS RM, WIJBRANDTS CA, VAN SCHAARDENBURG D, GERLAG DM, TAK PP: Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. (2007) 56:772-778.
50. GONG Q, OU QL, YE SM et al.: Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. (2005) 174:817-826.
51. HAMAGUCHI Y, UCHIDA J, CAIN DW et al.: The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol. (2005) 174:4389-4399.
52. ANOLIK JH, CAMPBELL D, FELGAR RE et al.: The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. (2003) 48:455-459.
53. EDWARDS JC, LEANDRO MJ, CAMBRIDGE G: Repeated B lymphocyte depletion therapy in rheumatoid arthritis: 5 year follow-up. Arthritis Rheum. (2005) 52:S133-S134.
54. GENOVESE MC, KAINE JL, KOHEN MD et al.: Safety and clinical activity of ocrelizumab (a humanized antibody targeting CD20+ B cells) in combination with methotrexate (MTX) in moderate-severe rheumatoid arthritis (RA) patients (pts) (Ph I/II ACTION study). Arthritis Rheum. (2006) 54:S66-S67.
55. GOLDENBERG DM, ON ZX, HORAK ID, HANSEN H, STEIN R: Anti-lymphoma activity of a new humanized anti-CD20 monoclonal antibody, hA20. FASEB J. (2003) 17:C123.
56. MANNING WC, NATARAJAN R, RAO T et al.: Serum B A FF levels correlate with B cell depletion in patients with rheumatoid arthritis treated with ocrelizumab. Arthritis Rheum. (2006) 54:S67.
57. VUGMEYSTER Y, BEYER J, HOWELL K et al.: Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J. Immunother. (2005) 28:212-219.
58. ROLL P, PALANICHAMY A, KNEITZ C, DÖRNER T, TONY HP: Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. (2006) 54:2377-2386.
59. LEANDRO MJ, COOPER N, CAMBRIDGE G, EHRENSTEIN MR, EDWARDS JCW: Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (2007) 46:29-36.
60. CAMBRIDGE G, LEANDRO MJ, EDWARDS JCW et al.: Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. (2003) 48:2146-2154.
61. ROUZIERE AS, KNEITZ C, DÖRNER T, TONY HP: The effect of B-cell depletion with an anti-CD20 antibody on the immunoglobulin heavy-chain repertoire in a patient with rheumatoid arthritis. Arthritis. Res. Ther. (2005) 7:S46.
62. LEANDRO MJ, EDWARDS JCW, CAMBRIDGE G, EHRENSTEIN MR: B-cell repopulation occurs mainly from naive B cells in patients with rheumatoid arthritis and systemic lupus erythematosus treated with rituximab. Arthritis Rheum. (2003) 48:S464.
63. CAMBRIDGE G, STOHL W, LEANDRO MJ, MIGONE TS, HILBERT DM, EDWARDS JCW: Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment - relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. (2006) 54:723-732.
64. ANOLIK JH, BARNARD J, CAPPIONE A et al.: Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. (2004) 50:3580-3590.
65. LOPES-CARVALHO T, FOOTE J, KEARNEY JF: Marginal zone B cells in lymphocyte activation and regulation. Curr. Opin. Immunol. (2005) 17:244-250.
66. ITO T, ISHIKAWA S, SATO T et al.: Defective B1 cell homing to the peritoneal cavity and preferential recruitment of B1 cells in the target organs in a murine model for systemic lupus erythematosus. J. ImmunoL (2004) 172:3628-3634.
67. - plasma cells in human secondary lymphoid tissue. Blood (2007) 109(11):4856-4864.
68. TEDDER TF, POE JC, HAAS KM: CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv. Immunol. (2005) 88:1-50.
69. DÖRNER T, LIPSKY PE: Signalling pathways in B cells: implications for autoimmunity. Curr. Top. Microbiol. Immunol. (2006) 305:213-240.
70. ENGEL P, WAGNER N, MILLER AS, TEDDER TF: Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand. J Exp. Med. (1995) 181:1581-1586.
71. WILSON GL, FAUCI AS, KEHRL JH: Isolation and characterization of cDNA and genomic clones for the B-cell membrane protein-CD22. FASEB J. (1991) 5:A1696.
72. STEIN R, BELISLE E, HANSEN HJ, GOLDENBERG DM: Epitope specificity of the anti-(B-cell lymphoma) monoclonal-antibody, L12. Cancer Immunol. Immunother. (1993) 37:293-298.
73. ACOBI AM, GOLDENBERG DM, HIEPE FT, RADBRUCH A, BURMESTER GR, DORNER T: Differential effects of epratuzumab on peripheral blood B cells of SLE patients versus normal controls. Ann. Rheum. Dis. (2007) [Epub Ahead of Print].
74. CHAOUCHI N, VAZQUEZ A, GALANAUD P, LEPRINCE C: B-cell antigen receptor-mediated apoptosis - importance of accessory molecules CD 19 and CD22, and of surface Igm cross-linking. J. Immunol. (1995) 154:3096- 3104.
75. DOODY GM, JUSTEMENT LB, DELIBRIAS CC et al.: A role in B-cell activation for CD22 and the protein-tyrosine-phosphatase SHP. Science (1995) 269:242-244.
76. TUSCANO JM, RIVA A, TOSCANO SN, TEDDER TF, KEHRL JH: CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK/SAPK signaling cascade. Blood (1999) 94:1382-1392.
77. CARNAHAN J, STEIN R, QU ZX et al.: Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol. Immunol. (2007) 44:1331-1341.
78. DÖRNER T, KAUFMANN J, WEGENER WA, TEOH N, GOLDENBERG DM, BURMESTER GR: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. (2006):8(3):R74.
79. STEINFELD SD, TANT L, BURMESTER GR et al.: Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label Phase I/II study. Arthritis Res. Ther. (2006): 8(3):R129.
80. LEE CV, HYMOWITZ SG, WALLWEBER HJ et al.: Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood (2006) 108:3103-3111.
81. HALPERN WG, LAPPIN P, ZANARDI T et al.: Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol. Sci. (2006) 91:586-599.
82. VUGMEYSTER Y, SESHASAYEE D, CHANG W et al.: A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am. J. Pathol. (2006) 168:476-489.
83. O'CONNOR BP, RAMAN VS, ERICKSON LD et al.: BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. (2004) 199:91-97.
84. HABERMAN AM, SHLOMCHIK MJ: Opinion - reassessing the function of immune-complex retention by follicular dendritic cells. Nat. Rev. Immunol. (2003) 3:757-764.
85. MAO CC, JIANG LY, MELO-JORGE M et al.: T cell-independent somatic hypermutation in murine B cells with an immature phenotype. Immunity (2004) 20:133-144.
86. SFIKAKIS PP, BOLETIS JN, LIONAKI S et al.: Remission of proliferative lupus nephritis following anti-B cell therapy is preceded by downregulation of the T cell costimulatory molecule CD40-ligand. Arthritis Rheum. (2004) 50:S227.
87. QUEZADA SA, JARVINEN LZ, LIND EE, NOELLE RJ: CD40/CD154 interactions at the interface of tolerance and immunity. Ann. Rev. Immunol. (2004) 22:307-328.
88. BOUMPAS DT, FURIE R, MANZI S et al.: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. (2003) 48:719-727.
89. WANG Y, CARTER RH: CD 19 regulates B cell maturation, proliferation, and positive selection in the FDC zone of murine splenic germinal centers. Immunity (2005) 22:749-761.
90. DAVIDSON A, DIAMOND B, WOFSY D, DAIKH D: Block and tackle: CTLA41g takes on lupus. Lupus (2005) 14:197-203.
91. WARNATZ K, BOSSALLER L, SALZER U et al.: Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood (2006) 107:3045-3052.
92. HUTLOFF A, BUCHNER K, REITER K et al.: Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum. (2004) 50:3211-3220.
93. IWAI H, ABE M, HIROSE S et al.: Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J. Immunol. (2003) 171:2848-2854.
94. KISHIMOTO T: Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res. Ther. (2006) 8(2):S2.
95. LIPSKY PE: Interleukin-6 and rheumatic diseases. Arthritis Res. Ther. (2006) 8(2):S4.
96. VELDHOEN M, HOCKING RJ, ATKINS CJ, LOCKSLEY RM, STOCKINGER B: TGF β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producingT cells. Immunity (2006) 24:179-189.
97. YOKOTA S, MIYAMAE T, KUROSAWA R et al.: Long-term treatment of systemic onset juvenile idiopathic arthritis (SO-JIA) with humanized anti-IL-6 receptor monoclonal antibody, tocilizumab (Actemra®). Arthritis Rheum. (2005) 52:5725.
98. ETTINGER R, SIMS GP, FAIRHURST AM et al.: IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol. (2005) 175:7867-7879.
99. OZAKI K, SPOLSKI R, ETTINGER R et al.: Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of blimp-1 and bcl-61. J. Immunol. (2004) 173:5361-5371.
100. BAECHLER EC, BATLIWALLA FM, REED AM et al.: Gene expression profiling in human autoimmunity. Immunol. Rev. (2006) 210:120-137.
101. RONNBLOM L, ALM GV: An etiopathogenic role for the type II FN system in SLE. Trends Immunol. (2001) 22:427-431.
102. RONNBLOM L, ALM GV: Systemic lupus erythematosus and the type I interferon system. Arthritis. Res. Ther. (2003) 5:68-75.
103. HRON JD, PENG SL: Type I IFN protects against murine lupus. J. Immunol. (2004) 173:2134-2142.
104. LI JW, LIU Y, XIE C et al.: Deficiency of type I interferon contributes to Sle2-associated component lupus phenotypes. Arthritis Rheum. (2005) 52:3063-3072.
105. GOTTENBERG JE, CAGNARD N, LUCCHESI C et al.: Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc. Nat. Acad. Sci. USA (2006) 103:2770-2775.
106. WENZEL J, SCHMIDT R, PROELSS J, ZAHN S, BIEBER T, TUTING T: Type I interferon-associated skin recruitment of CXCR3+lymphocytes in dermatomyositis. Clin. Exp. Dermatol. (2006) 31:576-582.
107. BAVE U, MAGNUSSON M, ELORANTA ML, PERERS A, ALM GV, RONNBLOM L: FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG. J. Immunol. (2003) 171:3296-3302.
108. FARKAS L, BEISKE K, LUND-JOHANSEN F, BRANDTZAEG P, JAHNSEN FL: Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. (2001) 159:237-243.
109. BANCHEREAU J, PASCUAL V, PALUCKA AK: Autoimmunity through cytokine-induced dendritic cell activation. Immunity (2004) 20:539-550.
110. BARRAT FJ, MEEKER T, GREGORIO J et al.: Nucleic acids of mammalian origin can act as endogenous ligands for toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. (2005) 202:1131-1139.
111. NIMMERJAHN F, RAVETCH JV: Feγ receptors: old friends and new family members. Immunity (2006) 24:19-28.
112. FUKUYAMA H, NIMMERJAHN F, RAVETCH JV: The inhibitory Fcγ receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G(+) anti-DNA plasma cells. Nat. Immunol. (2005) 6:99-106.
113. MCGAHA TL, SORRENTINO B, RAVETCH JV: Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science (2005) 307:590-593.
114. MACKAY M, STANEVSKY A, WANG T et al.: Selective dysregulation of the FcγIIB receptor on memory B cells in SLE. J. Exp. Med. (2006) 203:2157-2164.
115. ZHANG K, KEPLEY CL, TERADA T, ZHU DC, PEREZ H, SAXON A: Inhibition of allergen-specific IgE reactivity by a human Ig Fcγ-Fc epsilon bifunctional fusion protein. J. Allergy Clin. Immunol. (2004) 114:321-327.
116. KIMBY E: Tolerability and safety of rituximab (MabThera®). Cancer Treatment Rev. (2005) 31:456-473.
117. HOFER T, MUEHLINGHAUS G, MOSER K et al.: Adaptation of humoral memory. Immunol. Rev. (2006) 211:295-302.
118. ROLL P, PALANICHAMY A, KNEITZ C, DÖRNER T, TONY HP: Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. (2006) 54:2377-2386.
119. ROSEN O, HIEPE F, MASSENKEIL G, THIEL A, ARNOLD R: Relapse of systemic lupus erythematosus. Lancet (2001) 357:807-808.